Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001135 · ClinicalTrials.gov registry record · Phase 3
A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 2,009
- Enrollment target
NCT00001135 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,009 participants.
The verdict
NCT00001135, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,009 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their infants can help reduce the chance that a mother will give HIV to her baby during delivery. NVP is a promising medication for blocking HIV transmission from HIV-positive mothers to their infants. NVP is inexpensive and is easily absorbed by the mother and transferred to the infant. It is thought that even a single dose to the mother and infant may provide enough protection to the baby during the time of exposure to HIV at birth.
Interventions
- DRUG Nevirapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,009 participants |
| Est. Completion | 2001-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001135
The ClinicalTrials.gov registry entry for NCT00001135 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,009 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nevirapine is the first listed.
NCT00001135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001135 about?
NCT00001135 is a clinical study titled "A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants". The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their infants can help reduce the chance that a mother will give HIV to her baby during delivery. NVP is a promising medication for blocking HIV transmission from HIV-positive mothers...
What is the current status of trial NCT00001135?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,009 participants. Estimated completion is 2001-05.
What interventions are being tested in trial NCT00001135?
The interventions under investigation include: Nevirapine (DRUG).
Who is sponsoring clinical trial NCT00001135?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.